Studies have reported that 6 patients with NSCLC and brain metastases received 100% intracranial ORR (4 cases of PR and 2 cases of CR) after receiving osimertinib and bevacizumab combination treatment.[10] The patient in our case with intergenic ALK fusion had a good response to ALK TKI plus endostar. The gene discussed is ALK; the disease is non-small cell lung carcinoma.